Tag: psoriatic arthritis treatment industry

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Psoriatic Arthritis Treatment Market Poised To Hit $20.62 Billion By 2030 With A 9.5% CAGR

The psoriatic arthritis treatment market size has seen significant expansion in recent years. It is anticipated to increase from $13.17 billion in 2025 to $14.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The expansion observed during the past period was largely due to factors including the restricted availability of cutting-edge therapies, continued dependence on traditional NSAIDs and DMARDs, the rising occurrence of psoriatic arthritis, enhanced patient understanding, and the development of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market is anticipated to experience substantial expansion in the coming years, with projections indicating a rise to $20.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is fueled by the emergence of interleukin inhibitors and JAK inhibitors, the increasing acceptance of biologics, the evolution of personalized medicine approaches, the growing adoption of telemedicine for managing chronic conditions, and enhanced governmental and insurance support for psoriatic arthritis therapies. Key trends identified for this period include the rising utilization of biologics and targeted synthetic DMARDs, a heightened awareness regarding the early diagnosis and effective management of psoriatic arthritis, the development of individualized treatment strategies for both joint and skin manifestations, the broadening of hospital and specialty pharmacy distribution networks, and the integration of telemedicine with remote monitoring for patients with psoriatic arthritis.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=34290673&type=smp&name=Psoriatic%20Arthritis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Psoriatic Arthritis Treatment Market Development Factors: What’s Supporting Demand?

Rising healthcare expenditure is projected to boost the expansion of the psoriatic arthritis treatment market in the future. Healthcare spending, interchangeably called healthcare expenditure, signifies the financial allocation dedicated to funding healthcare services, products, and programs within a particular nation, area, or healthcare framework. This funding aids the diagnostic process by covering costs for medical appointments, lab tests, and imaging. Individuals with PsA frequently undergo thorough assessments to confirm their condition, determine the degree of joint impact, and identify any related health issues. As an illustration, in December 2024, data from the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, revealed that U.S. health care expenditures in 2023 saw a 7.5% rise, reaching $4.9 trillion, which translates to approximately $14,570 per person. Consequently, the expansion of healthcare spending is propelling the development of the psoriatic arthritis treatment market.

Psoriatic Arthritis Treatment Market Segment Analysis: What Are The Core Market Categories?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

Psoriatic Arthritis Treatment Market Transformation Trends: What Innovations Are Driving Change?

Leading companies engaged in the psoriatic arthritis treatment market are securing approvals for new medications such as Cosentyx to enhance their market profitability. Cosentyx is a pharmaceutical product utilized for treating autoimmune conditions, including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For instance, in October 2023, Novartis, a Switzerland-based pharmaceutical corporation, announced that its novel drug Cosentyx had received approval from the Food and Drug Administration. Cosentyx operates as a human interleukin-17A antagonist, working by impeding the activation of a protein called IL-17A, thereby reducing potential patient side effects like edema, discomfort, and skin rashes. Cosentyx has been proven beneficial in managing the symptoms of psoriatic arthritis and can begin to show effects in as little as three weeks. It alleviates several psoriatic arthritis symptoms, such as joint pain and tenderness, back discomfort, and skin problems.

Psoriatic Arthritis Treatment Market Top Companies Driving Competitive Growth

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

View The Full Psoriatic Arthritis Treatment Market Report:

https://thebusinessresearchcompany.com/report/Psoriatic-Arthritis-Treatments-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Psoriatic Arthritis Treatment Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Psoriatic Arthritis Treatment Market Forecast: What Market Value Is Expected By 2030?

The psoriatic arthritis treatment market has experienced notable expansion over the past few years. Projected to climb from $13.17 billion in 2025 to $14.36 billion in 2026, it is anticipated to achieve a compound annual growth rate (CAGR) of 9.0%. This historical growth has been driven by several factors, including restricted access to advanced treatment options, heavy dependence on traditional NSAIDs and DMARDs, a rising incidence of psoriatic arthritis, heightened awareness among patients, and the broadening of hospital and retail pharmacy networks.

The market for psoriatic arthritis treatments is set to undergo substantial expansion in the coming years, reaching an estimated $20.62 billion by 2030 with a compound annual growth rate (CAGR) of 9.5%. This projected growth during the forecast period is driven by factors such as the advancement of interleukin and JAK inhibitors, a rising reliance on biologic therapies, the emergence of personalized medicine, increased use of telemedicine for managing chronic conditions, and heightened financial backing from governments and insurers. Key trends shaping this period include the growing acceptance of biologics and targeted synthetic DMARDs, a greater focus on early detection and management of psoriatic arthritis, the development of tailored treatments addressing both joint and skin manifestations, an expanded reach through hospital and specialized pharmacy channels, and the incorporation of telehealth along with remote patient monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Psoriatic Arthritis Treatment Market Growth Drivers And Industry Catalysts

The expected rise in healthcare spending is set to drive forward the expansion of the psoriatic arthritis treatment market in the coming period. Healthcare spending, which can also be referred to as healthcare expenditure, involves the financial resources that are directed toward supporting the delivery of medical services, products, and programs within a given country, region, or healthcare framework. This funding aids the diagnostic process by covering the costs associated with medical consultations, laboratory tests, and imaging procedures that are needed for accurate disease identification. For individuals with PsA, a detailed assessment is frequently conducted to confirm the diagnosis, evaluate the degree of joint damage, and identify any coexisting health conditions that may be present. As an example, data from December 2024 provided by the Centers for Medicare & Medicaid Services, a U.S. agency responsible for overseeing the Medicare and Medicaid programs, indicated that healthcare expenditures in the United States rose by 7.5% in 2023, reaching $4.9 trillion, which equates to approximately $14,570 per person. Consequently, this growth in healthcare spending is stimulating the advancement of the psoriatic arthritis treatment market.

Psoriatic Arthritis Treatment Market Segments: Where Are The Largest Growth Opportunities?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

Psoriatic Arthritis Treatment Market Trends Influencing Long-Term Demand

Major pharmaceutical players in the psoriatic arthritis treatment sector are securing approvals for new therapies, including Cosentyx, as a strategy to enhance their market profitability. Cosentyx is prescribed for autoimmune disorders such as non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For example, in October 2023, the Switzerland-based company Novartis reported that the Food and Drug Administration had granted approval for their novel drug, Cosentyx. This medication operates as a human interleukin-17A antagonist, working to inhibit the activity of the IL-17A protein, which in turn minimizes potential adverse effects in patients, including swelling, discomfort, and skin rashes. Clinical evidence demonstrates that Cosentyx effectively alleviates psoriatic arthritis symptoms, with some patients noticing improvement within just three weeks. The drug addresses multiple manifestations of the condition, such as joint pain and tenderness, back discomfort, and dermatological issues.

Psoriatic Arthritis Treatment Market Major Participants And Competitive Dynamics

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Access The Complete Psoriatic Arthritis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Psoriatic Arthritis Treatment Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Psoriatic Arthritis Treatment Market By 2030?

The psoriatic arthritis treatment market has experienced robust expansion in recent years. It is projected to grow from $13.17 billion in 2025 to $14.36 billion in 2026, at a compound annual growth rate (CAGR) of 9.0%. The historical growth of this market can be attributed to several factors including the limited availability of advanced therapies, a reliance on conventional NSAIDs and DMARDs, the increasing prevalence of psoriatic arthritis, growing patient awareness, and the expansion of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $20.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. Factors contributing to this anticipated growth include advancements in interleukin inhibitors and JAK inhibitors, the growing use of biologics, the emergence of personalized medicine strategies, increased utilization of telemedicine for managing chronic conditions, and enhanced government and insurance assistance for psoriatic arthritis care. Key trends expected during this period encompass the escalating uptake of biologics and targeted synthetic DMARDs, heightened recognition of early diagnosis and effective management of psoriatic arthritis, the evolution of tailored treatment methods for both joint and skin manifestations, the expansion of hospital and specialized pharmacy distribution networks, and the incorporation of telemedicine and remote monitoring for individuals with psoriatic arthritis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

Which Growth Drivers Are Expected To Support The Psoriatic Arthritis Treatment Market Forward?

The rise in healthcare expenditure is expected to propel the growth of the psoriatic arthritis treatment market going forward. Healthcare spending, also referred to as healthcare expenditure, represents the financial resources allocated to support the provision of healthcare services, products, and programs within a specific country, region, or healthcare system. This funding supports the diagnostic process by covering medical appointments, laboratory tests, and imaging studies. Patients with PsA often undergo a comprehensive evaluation to confirm the diagnosis, determine the extent of joint involvement, and assess any associated comorbidities. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the increase in healthcare spending is driving the growth of the psoriatic arthritis treatment market.

What Segment Types Are Included In The Psoriatic Arthritis Treatment Market Analysis?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

Which Trends Are Guiding The Development Of The Psoriatic Arthritis Treatment Market?

Major companies in the psoriatic arthritis treatment market are securing approvals for new drugs like Cosentyx to enhance their market profitability. Cosentyx is a medication utilized for treating autoimmune conditions such as non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For example, in October 2023, Novartis, a pharmaceutical company from Switzerland, announced that its new drug Cosentyx had received approval from the Food and Drug Administration. Cosentyx acts as a human interleukin-17A antagonist, preventing the activation of the IL-17A protein, which helps reduce potential patient side effects like edema, discomfort, and skin rashes. Cosentyx has demonstrated effectiveness in addressing psoriatic arthritis symptoms and can begin working in as little as three weeks. It alleviates various psoriatic arthritis symptoms, including joint pain and tenderness, back discomfort, and skin problems.

Which Organizations Are Involved In The Psoriatic Arthritis Treatment Market?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Access The Complete Psoriatic Arthritis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Which Region Holds The Largest Share In The Psoriatic Arthritis Treatment Market?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Psoriatic Arthritis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Psoriatic Arthritis Treatment Market Between 2026 And 2030?

The psoriatic arthritis treatment market has demonstrated significant expansion over recent years. This market is anticipated to increase from $13.17 billion in 2025 to $14.36 billion in 2026, registering a compound annual growth rate (CAGR) of 9.0%. The historical growth of this market was driven by the restricted availability of advanced therapies, the reliance on conventional NSAIDs and DMARDs, the rising occurrence of psoriatic arthritis, heightened patient awareness, and the development of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market is projected to experience robust expansion over the coming years. This market is anticipated to reach $20.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. Factors driving this growth during the forecast period include advancements in interleukin and JAK inhibitor development, a rise in the use of biologics, the expansion of personalized medicine strategies, increased uptake of telemedicine for managing chronic conditions, and enhanced government and insurance backing for psoriatic arthritis therapies. Key trends identified for the forecast period encompass a growing preference for biologics and targeted synthetic DMARDs, heightened recognition of the importance of early diagnosis and management for psoriatic arthritis, the evolution of tailored treatment methods for both joint and skin manifestations, the broadening of hospital and specialty pharmacy networks, and the incorporation of telemedicine alongside remote monitoring solutions for individuals with psoriatic arthritis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What Significant Factors Are Influencing The Psoriatic Arthritis Treatment Market Expansion?

The rising healthcare spending is anticipated to stimulate the expansion of the psoriatic arthritis treatment market in the future. Healthcare spending, also referred to as healthcare expenditure, denotes the financial assets dedicated to providing healthcare services, products, and initiatives within a particular nation, region, or healthcare framework. This spending aids the diagnostic process by funding doctor visits, lab tests, and imaging studies. Individuals with PsA frequently require comprehensive evaluations to confirm their diagnosis, determine the extent of joint involvement, and identify any related conditions. As an illustration, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency managing Medicare and Medicaid, reported that U.S. health care expenditures in 2023 rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per person. Consequently, the increase in healthcare spending is fueling the growth of the psoriatic arthritis treatment market.

How Is Segmentation Applied In The Psoriatic Arthritis Treatment Market Segment Analysis?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

Which Trends Are Impacting The Progress Of The Psoriatic Arthritis Treatment Market?

Leading companies in the psoriatic arthritis treatment market are securing approvals for new medications like Cosentyx to enhance their profitability. Cosentyx is a medication utilized to manage autoimmune conditions such as non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For instance, in October 2023, Novartis, a Switzerland-based pharmaceutical company, announced the Food and Drug Administration had approved its new drug, Cosentyx. Cosentyx functions as a human interleukin-17A antagonist, working by preventing the activation of a protein named IL-17A, which minimizes potential patient side effects like edema, discomfort, and skin rashes. Cosentyx has demonstrated efficacy in managing psoriatic arthritis symptoms and can show effects in as little as three weeks. It alleviates several psoriatic arthritis symptoms, including joint pain and tenderness, back discomfort, and skin issues.

Who Are The Companies Participating In The Psoriatic Arthritis Treatment Market Environment?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Get The Full Psoriatic Arthritis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Where Is The Psoriatic Arthritis Treatment Market Most Concentrated Geographically?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Psoriatic Arthritis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Psoriatic Arthritis Treatment Market By The End Of 2030?

The psoriatic arthritis treatment market size has seen significant expansion in recent years. It is anticipated to grow from $13.17 billion in 2025 to $14.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be ascribed to factors including the limited availability of advanced therapies, reliance on conventional NSAIDs and DMARDs, the increasing prevalence of psoriatic arthritis, growing patient awareness, and the expansion of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market size is projected to experience substantial growth in the upcoming years. It is forecast to expand to $20.62 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.5%. This growth throughout the forecast period stems from the advancement of interleukin inhibitors and jak inhibitors, the increasing acceptance of biologics, the proliferation of personalized medicine strategies, a surge in telemedicine adoption for managing chronic diseases, and increased government and insurance backing for psoriatic arthritis care. Prominent trends expected during the forecast period involve the rising uptake of biologics and targeted synthetic dmards, enhanced awareness surrounding the early diagnosis and management of psoriatic arthritis, the development of personalized treatment options for joint and skin symptoms, the broadening of hospital and specialty pharmacy distribution channels, and the integration of telemedicine and remote monitoring services for psoriatic arthritis patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What Drivers Are Shaping The Future Growth Of The Psoriatic Arthritis Treatment Market?

The augmented healthcare spending is projected to stimulate the expansion of the psoriatic arthritis treatment market moving forward. Healthcare spending, also referred to as healthcare expenditure, signifies the financial resources allocated to support the provision of healthcare services, products, and programs within a specific country, region, or healthcare system. This expenditure aids the diagnostic process by funding medical appointments, laboratory tests, and imaging studies. Patients with PsA often undergo comprehensive evaluations to confirm the diagnosis, determine the extent of joint involvement, and assess any associated comorbidities. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Consequently, the uptick in healthcare spending is propelling the growth of the psoriatic arthritis treatment market.

Which Segment Classifications Shape The Psoriatic Arthritis Treatment Market?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

How Are Trends Impacting The Psoriatic Arthritis Treatment Market?

Leading companies in the psoriatic arthritis treatment market are securing approvals for new drugs like Cosentyx to enhance their profitability. Cosentyx is a medication utilized for managing autoimmune conditions such as non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For instance, in October 2023, Novartis, a Switzerland-based pharmaceutical firm, announced that its novel drug Cosentyx had received approval from the Food and Drug Administration. Cosentyx functions as a human interleukin-17A antagonist, working by preventing the activation of the IL-17A protein, which helps minimize potential patient side effects including edema, discomfort, and skin rashes. Cosentyx has demonstrated effectiveness in addressing psoriatic arthritis symptoms, with its action commencing in as little as three weeks. It offers relief from several psoriatic arthritis symptoms, such as joint pain and tenderness, back discomfort, and skin problems.

Which Companies Are Expanding Their Footprint In The Psoriatic Arthritis Treatment Market?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Read the full psoriatic arthritis treatment market report here:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Which Geographic Regions Are Influencing Demand In The Psoriatic Arthritis Treatment Market?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Psoriatic Arthritis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the psoriatic arthritis treatment market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Psoriatic Arthritis Treatment Market by the end of 2030?

The psoriatic arthritis treatment market size has experienced substantial growth in recent years. It is forecast to expand from $13.17 billion in 2025 to $14.36 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.0%. The market’s historical growth can be attributed to several factors, including the limited availability of advanced therapies, continued reliance on conventional NSAIDs and DMARDs, the increasing prevalence of psoriatic arthritis, growing patient awareness, and the expansion of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market size is anticipated to experience robust expansion in the coming years. It is projected to expand to $20.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is attributable to factors such as the development of interleukin inhibitors and JAK inhibitors, the increasing adoption of biologics, the progress of personalized medicine approaches, the rising use of telemedicine for managing chronic diseases, and increased government and insurance backing for psoriatic arthritis treatment. Significant trends expected during this period include the growing acceptance of biologics and targeted synthetic DMARDs, enhanced awareness of early diagnosis and management of psoriatic arthritis, the evolution of personalized treatment strategies for both joint and skin symptoms, the broadening of hospital and specialty pharmacy distribution channels, and the integration of telemedicine and remote monitoring for psoriatic arthritis patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What Drivers Are Shaping Future Opportunities In The Psoriatic Arthritis Treatment Market?

The expansion in healthcare spending is projected to propel the growth of the psoriatic arthritis treatment market going forward. Healthcare spending, also recognized as healthcare expenditure, pertains to the financial resources designated to support the provision of healthcare services, products, and programs within a specific country, region, or healthcare system. This spending aids the diagnostic process by financing medical appointments, laboratory tests, and imaging studies. Individuals with PsA frequently undergo a comprehensive evaluation to confirm their diagnosis, determine the extent of joint involvement, and assess any associated comorbidities. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that U.S. health care expenditures in 2023 rose by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, this increase in healthcare spending is driving the growth of the psoriatic arthritis treatment market.

Which Segment Groups Are Influencing The Psoriatic Arthritis Treatment Market?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

What Upcoming Trends Are Likely To Define The Future Path Of The Psoriatic Arthritis Treatment Market?

Prominent companies operating within the psoriatic arthritis treatment market are obtaining authorizations for new drugs, such as Cosentyx, to bolster their market profitability. Cosentyx is a medication utilized in the management of autoimmune diseases including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. As an example, in October 2023, Novartis, a pharmaceutical company based in Switzerland, disclosed that the Food and Drug Administration had granted approval for its latest drug, Cosentyx. This drug operates as a human interleukin-17A antagonist, functioning by preventing the activation of a protein identified as IL-17A, which serves to diminish potential patient adverse reactions like edema, discomfort, and skin rashes. Cosentyx has been demonstrated to effectively manage the symptoms of psoriatic arthritis, with its effects potentially commencing in as little as three weeks, providing relief for various symptoms such as joint pain and tenderness, back discomfort, and skin problems.

Who Are The Core Companies Influencing Trends In The Psoriatic Arthritis Treatment Market?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Which Regions Are Projected To Dominate The Psoriatic Arthritis Treatment Market In The Coming Years?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Psoriatic Arthritis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the psoriatic arthritis treatment market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Psoriatic Arthritis Treatment Market by the end of 2030?

The psoriatic arthritis treatment market size has experienced substantial growth in recent years. It is forecast to expand from $13.17 billion in 2025 to $14.36 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.0%. The market’s historical growth can be attributed to several factors, including the limited availability of advanced therapies, continued reliance on conventional NSAIDs and DMARDs, the increasing prevalence of psoriatic arthritis, growing patient awareness, and the expansion of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market size is anticipated to experience robust expansion in the coming years. It is projected to expand to $20.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is attributable to factors such as the development of interleukin inhibitors and JAK inhibitors, the increasing adoption of biologics, the progress of personalized medicine approaches, the rising use of telemedicine for managing chronic diseases, and increased government and insurance backing for psoriatic arthritis treatment. Significant trends expected during this period include the growing acceptance of biologics and targeted synthetic DMARDs, enhanced awareness of early diagnosis and management of psoriatic arthritis, the evolution of personalized treatment strategies for both joint and skin symptoms, the broadening of hospital and specialty pharmacy distribution channels, and the integration of telemedicine and remote monitoring for psoriatic arthritis patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What Drivers Are Shaping Future Opportunities In The Psoriatic Arthritis Treatment Market?

The expansion in healthcare spending is projected to propel the growth of the psoriatic arthritis treatment market going forward. Healthcare spending, also recognized as healthcare expenditure, pertains to the financial resources designated to support the provision of healthcare services, products, and programs within a specific country, region, or healthcare system. This spending aids the diagnostic process by financing medical appointments, laboratory tests, and imaging studies. Individuals with PsA frequently undergo a comprehensive evaluation to confirm their diagnosis, determine the extent of joint involvement, and assess any associated comorbidities. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that U.S. health care expenditures in 2023 rose by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, this increase in healthcare spending is driving the growth of the psoriatic arthritis treatment market.

Which Segment Groups Are Influencing The Psoriatic Arthritis Treatment Market?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

What Upcoming Trends Are Likely To Define The Future Path Of The Psoriatic Arthritis Treatment Market?

Prominent companies operating within the psoriatic arthritis treatment market are obtaining authorizations for new drugs, such as Cosentyx, to bolster their market profitability. Cosentyx is a medication utilized in the management of autoimmune diseases including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. As an example, in October 2023, Novartis, a pharmaceutical company based in Switzerland, disclosed that the Food and Drug Administration had granted approval for its latest drug, Cosentyx. This drug operates as a human interleukin-17A antagonist, functioning by preventing the activation of a protein identified as IL-17A, which serves to diminish potential patient adverse reactions like edema, discomfort, and skin rashes. Cosentyx has been demonstrated to effectively manage the symptoms of psoriatic arthritis, with its effects potentially commencing in as little as three weeks, providing relief for various symptoms such as joint pain and tenderness, back discomfort, and skin problems.

Who Are The Core Companies Influencing Trends In The Psoriatic Arthritis Treatment Market?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Which Regions Are Projected To Dominate The Psoriatic Arthritis Treatment Market In The Coming Years?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Psoriatic Arthritis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the psoriatic arthritis treatment market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Psoriatic Arthritis Treatment Market by the end of 2030?

The psoriatic arthritis treatment market size has experienced substantial growth in recent years. It is forecast to expand from $13.17 billion in 2025 to $14.36 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.0%. The market’s historical growth can be attributed to several factors, including the limited availability of advanced therapies, continued reliance on conventional NSAIDs and DMARDs, the increasing prevalence of psoriatic arthritis, growing patient awareness, and the expansion of hospital and retail pharmacy infrastructure.

The psoriatic arthritis treatment market size is anticipated to experience robust expansion in the coming years. It is projected to expand to $20.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is attributable to factors such as the development of interleukin inhibitors and JAK inhibitors, the increasing adoption of biologics, the progress of personalized medicine approaches, the rising use of telemedicine for managing chronic diseases, and increased government and insurance backing for psoriatic arthritis treatment. Significant trends expected during this period include the growing acceptance of biologics and targeted synthetic DMARDs, enhanced awareness of early diagnosis and management of psoriatic arthritis, the evolution of personalized treatment strategies for both joint and skin symptoms, the broadening of hospital and specialty pharmacy distribution channels, and the integration of telemedicine and remote monitoring for psoriatic arthritis patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What Drivers Are Shaping Future Opportunities In The Psoriatic Arthritis Treatment Market?

The expansion in healthcare spending is projected to propel the growth of the psoriatic arthritis treatment market going forward. Healthcare spending, also recognized as healthcare expenditure, pertains to the financial resources designated to support the provision of healthcare services, products, and programs within a specific country, region, or healthcare system. This spending aids the diagnostic process by financing medical appointments, laboratory tests, and imaging studies. Individuals with PsA frequently undergo a comprehensive evaluation to confirm their diagnosis, determine the extent of joint involvement, and assess any associated comorbidities. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that U.S. health care expenditures in 2023 rose by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, this increase in healthcare spending is driving the growth of the psoriatic arthritis treatment market.

Which Segment Groups Are Influencing The Psoriatic Arthritis Treatment Market?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

What Upcoming Trends Are Likely To Define The Future Path Of The Psoriatic Arthritis Treatment Market?

Prominent companies operating within the psoriatic arthritis treatment market are obtaining authorizations for new drugs, such as Cosentyx, to bolster their market profitability. Cosentyx is a medication utilized in the management of autoimmune diseases including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. As an example, in October 2023, Novartis, a pharmaceutical company based in Switzerland, disclosed that the Food and Drug Administration had granted approval for its latest drug, Cosentyx. This drug operates as a human interleukin-17A antagonist, functioning by preventing the activation of a protein identified as IL-17A, which serves to diminish potential patient adverse reactions like edema, discomfort, and skin rashes. Cosentyx has been demonstrated to effectively manage the symptoms of psoriatic arthritis, with its effects potentially commencing in as little as three weeks, providing relief for various symptoms such as joint pain and tenderness, back discomfort, and skin problems.

Who Are The Core Companies Influencing Trends In The Psoriatic Arthritis Treatment Market?

Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Which Regions Are Projected To Dominate The Psoriatic Arthritis Treatment Market In The Coming Years?

North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Psoriatic Arthritis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp

Browse Through More Reports Similar to the Global Psoriatic Arthritis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Psoriatic Arthritis Treatment Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the psoriatic arthritis treatment market has experienced significant growth. The market size, which stood at $10.93 billion in 2024, is projected to increase to $12 billion in 2025, at a compound annual growth rate (CAGR) of 9.8%. Factors such as improved diagnostics, a rising occurrence of psoriatic arthritis, enhanced awareness regarding the disease and its remedies, an increased selection of approved treatments, government backing for R&D, and amplified funding from pharmaceutical firms, contributed to the growth experienced during the historical period.

What Is the Forecast for the Psoriatic Arthritis Treatment Market Size Through 2029?

The market for the treatment of psoriatic arthritis is projected to experience significant expansion in the forthcoming years, reaching a value of $17.16 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 9.4%. The surge in growth forecasted for this period is due to factors such as the rise of personalized medicine, the development of biologics and small molecules, increased variety in treatment options, and a globally aging population. Key future trends to track include progress in biologics, oral small molecules, pathway-specific targeting, telemedicine coupled with remote monitoring, patient-oriented care, and the use of real-world evidence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp

What are the Key Market Players in Psoriatic Arthritis Treatment Market and How They’re Evolving?

Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

What Are the Primary Growth Drivers in the Psoriatic Arthritis Treatment Market?

Inflammatory disorders like psoriasis and psoriatic arthritis have seen a surge in prevalence lately, which in turn has fueled the growth of the psoriatic arthritis treatment market. Psoriasis, which often coexists with an inflammatory type of arthritis referred to as psoriatic arthritis (PsA), affects 30% of those with psoriasis. As per the data released by the National Library of Medicine, a US-government agency, in January 2024, the yearly incidence of PsA among psoriasis patients fluctuates between 1.9% and 2.7% per 100 patients. The probability of developing PsA shows a notable rise over time, with rates standing at 1.7% after 5 years, escalating to 3.1% after 10 years, and skyrocketing to 20.5% 30 years post a psoriasis diagnosis. Therefore, the escalating prevalence of both psoriasis and psoriatic arthritis is a key factor propelling market growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp

What Are the Leading Segments in the Global Psoriatic Arthritis Treatment Industry?

The psoriatic arthritis treatment market covered in this report is segmented –

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors

What Are the Key Market Trends in the Psoriatic Arthritis Treatment Industry?

Significant organizations in the psoriatic arthritis treatment market are constantly making strides towards developing advanced solutions like targeted biologic therapy. This development is focused on offering more efficient and personalized treatment alternatives that tackle the root inflammatory issues, elevate patient results and improve the general life quality of those dealing with this persistent ailment. Targeted biologic therapy employs specifically formulated drugs or substances to interact with particular molecules that drive the growth and proliferation of cancer cells. The primary aim is to reduce harm to healthy cells while augmenting therapeutic effectiveness. An illustration of this is when AbbVie, a biopharmaceutical firm based in the US, announced the approval of SKYRIZI (risankizumab-rzaa) by the U.S. Food and Drug Administration (FDA) in January 2022. SKYRIZI® (risankizumab-rzaa) is an interleukin-23 inhibitor that is exclusively used for active psoriatic arthritis treatment. It targets the inflammation source by hindering the p19 component of IL-23. Clinical trials have shown significant enhancements in joint symptoms and overall disease activity, resulting in numerous patients attaining clinical remission and an improved life quality. The therapy can be delivered through a subcutaneous injection, offering a controllable choice for patients and accommodating adjustable dosage schedules as per individual requirements.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

What Is the Regional Outlook for the Psoriatic Arthritis Treatment Market?

The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3458

This Report Delivers Insight On:

1. How big is the psoriatic arthritis treatment market, and how is it changing globally?

2. Who are the major companies in the psoriatic arthritis treatment market, and how are they performing?

3. What are the key opportunities and risks in the psoriatic arthritis treatment market right now?

4. Which products or customer segments are growing the most in the psoriatic arthritis treatment market?

5. What factors are helping or slowing down the growth of the psoriatic arthritis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the psoriatic arthritis treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Key Projections for the CAGR of the Psoriatic Arthritis Treatment Market Size From 2025 to 2034?#_x000D_

The market for treating psoriatic arthritis has notably expanded in the recent past. It is projected to escalate from $10.93 billion in 2024 to $12 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. The historic expansion is credited to factors such as heightened diagnosis, surge in psoriatic arthritis cases, growing awareness about psoriatic arthritis and its medical solutions, broadening spectrum of approved treatments for psoriatic arthritis, government-backed research and development, and increased funding from pharmaceutical enterprises._x000D_

_x000D_

In the upcoming years, the market size for the psoriatic arthritis treatment is expected to steadily rise. By 2029, the growth is set to reach $17.16 billion with a Compound Annual Growth Rate (CAGR) of 9.4%. The key factors contributing to this predicted increase during the forecast period include the advent of individualized medicines, novel biologics and small molecules, broader treatment alternatives, and the rising global aging population. Notable trends within the forecast period encompass advancements in biologics and oral small molecules, focus on specific pathways, the use of telemedicine and remote patient monitoring, an emphasis on patient-centered care, and the utilization of real-world evidence._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Psoriatic Arthritis Treatment Market?#_x000D_

The escalation in the incidence of psoriasis and psoriatic arthritis has stimulated the expansion of the psoriatic arthritis treatment market. Both psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory conditions that can drastically impact health and life quality. Psoriasis is linked with inflammatory arthritis, known as psoriatic arthritis (PsA), occurring in 30% of psoriasis patients. For example, in January 2024, the National Library of Medicine, a U.S. government entity, reported that the annual occurrence of psoriatic arthritis among psoriasis patients varies from 1.9% to 2.7% per 100 patients. The probability of PsA development increases over time, with rates of 1.7% at 5 years, 3.1% at 10 years, and up to 20.5% at 30 years post-psoriasis diagnosis. Therefore, the increasing incidence of psoriasis and psoriatic arthritis propels the growth of the market._x000D_

_x000D_

#Which Primary Segments of the Psoriatic Arthritis Treatment Market Are Driving Growth and Industry Transformations?#_x000D_

The psoriatic arthritis treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes_x000D_

2) By Route Of Administration: Oral, Parenteral, Topical_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors_x000D_

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs_x000D_

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics_x000D_

4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the Psoriatic Arthritis Treatment Market?#_x000D_

The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#Which Technological Trends Are Reshaping the Psoriatic Arthritis Treatment Industry Dynamics?#_x000D_

Leading corporations in the psoriatic arthritis treatment market are steadily concentrating on the creation and development of advanced therapeutic solutions like targeted biologic therapy. These novel treatment methods specifically focus on the underlying inflammatory process, ameliorating patient outcomes and boosting the overall quality of life for those suffering from this relentless ailment. Targeted biologic therapy employs specifically engineered medications or substances to interfere with certain molecules that contribute to the proliferation and dissemination of cancerous cells. The goal is to reduce harm to healthy cells while maximizing therapeutic effectiveness. For example, AbbVie, a biopharmaceutical company based in the US, announced in January 2022, that its product, SKYRIZI (risankizumab-rzaa), has received approval from the U.S. Food and Drug Administration (FDA). It’s an IL-23 inhibitor with a designated use for active psoriatic arthritis treatment. It works by inhibiting the p19 subunit of IL-23, targeting inflammation at its origin. There have been significant enhancements in joint symptoms and overall disease activity in the clinical studies, bringing many patients into clinical remission and improving their quality of life. As it is administered via a subcutaneous injection, the treatment offers a convenient patient-friendly option with flexible dosing options that can be adapted to individual needs._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Psoriatic Arthritis Treatment Market?#_x000D_

Psoriatic arthritis treatment refers to a method of treatment or drug used to stop or lessen a chronic inflammatory disease of the joints and the areas where tendons and ligaments attach to the bones (entheses). This treatment focuses on controlling skin involvement and treating joint pain and disability._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3458_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model